Create a free research account to view current pricing and place an order.
Mechanism of action
Cagrilintide is an amylin analog pathway compound. Amylin-receptor signaling complements incretin pathways by enhancing satiety, slowing gastric emptying, and supporting meal-size reduction through hindbrain and hypothalamic appetite circuits.
Half-life & pharmacokinetics
Half-life: Long acting; context dependent.
Long-acting weekly research profile. Precise pharmacokinetic interpretation depends on formulation and study context; slow escalation is preferred due to additive appetite and nausea effects.
Research dosing reference
0.25-2.4 mg once weekly; slow escalation due to additive nausea potential.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 0.25 mg | 5 units |
| 0.50 mg | 10 units |
| 1.00 mg | 20 units |
| 2.00 mg | 40 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Once weekly on a consistent day. Time of day is less important than consistency; choose timing that minimizes nausea disruption.
Beginner escalation
Start at the lowest practical exposure and hold each step long enough to evaluate GI tolerance before increasing.
Side-effect mitigation
Monitor nausea, reflux, constipation, reduced appetite, hydration status, fatigue, and delayed gastric emptying. Slow escalation and hydration/electrolytes are primary mitigation tools.
Stack compatibility
Frequently discussed alongside GLP-pathway protocols; additive nausea and appetite suppression require cautious structure.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Use slow, staged exposure with reassessment every 4-8 weeks, especially if combined with GLP-pathway compounds due to additive satiety and nausea potential.
Frequently asked questions
What is Cagrilintide and how does it work?
Cagrilintide is an amylin analog pathway compound. Amylin-receptor signaling complements incretin pathways by enhancing satiety, slowing gastric emptying, and supporting meal-size reduction through hindbrain and hypothalamic appetite circuits.
What is the half-life of Cagrilintide?
Cagrilintide: Long acting; context dependent. Long-acting weekly research profile. Precise pharmacokinetic interpretation depends on formulation and study context; slow escalation is preferred due to additive appetite and nausea effects.
How is Cagrilintide reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is Cagrilintide FDA approved?
No. Cagrilintide is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration